U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07009262) titled 'A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks' on May 07.
Brief Summary: Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.
Study Start Date: April 21
Study Type: OBSERVATIONAL
Condition:
Hereditary Angioedema
Intervention:
OTHER: Inapplicable
Inapplicable
Recruitment Status: ...